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Abstract
IL-15 operates via a unique mechanism termed transpresentation. In this system, IL-15 produced
by one cell type is bound to IL-15Rα expressed by the same cell and is presented to apposing cells
expressing the IL-15Rβ/γC complex. We have shown that administering soluble IL-15Rα
complexed with IL-15 can greatly enhance IL-15 activity. We now show that the naive CD8 T cell
response to exogenous IL-15/IL-15Rα complex is MHC class I dependent. In the absence of β2
microglobulin, naive CD8 T cells scarcely proliferated in response to IL-15/IL-15Rα complex,
whereas memory cells proliferated, although to a lesser extent, compared with levels in control
mice. The loss of β2m or FcRn slightly reduced the extended half-life of IL-15/IL-15Rα complex,
whereas FcRn deficiency only partially reduced the naive CD8 T cell proliferative response to
IL-15/IL-15Rα complex. In addition, we demonstrated a link between TCR avidity and the ability
of a T cell to respond to IL-15/IL-15Rα complex. Thus, T cells expressing low-avidity TCR
responded poorly to IL-15/IL-15Rα complex, which correlated with a poor homeostatic
proliferative response to lymphopenia. The inclusion of cognate peptide along with complex
resulted in enhanced proliferation, even when TCR avidity was low. IL-15/IL-15Rα complex
treatment, along with peptide immunization, also enhanced activation and the migratory ability of
responding T cells. These data suggest that IL-15/IL-15Rα complex has selective effects on Ag-
activated CD8 T cells. Our findings have important implications for directing IL-15/IL-15Rα
complex-based therapy to specific Ag targets and illustrate the possible adjuvant uses of IL-15/
IL-15Rα complex.
Overlapping factors regulate the naive and memory CD8 T cell pools in the periphery. Naive
CD8 T cells, but not memory CD8 T cells, require contact with self-peptide presented by
MHC class I molecules, whereas both populations require IL-7 for their survival (1–5).
Furthermore, memory CD8 T cells require IL-15 for their continued homeostatic
proliferation in an immunosufficient background (6). IL15−/− and IL-15Rα−/− mice have a
significantly smaller naive CD8 T cell compartment, possibly due to reduced CD8 T cell
thymic development and survival in the periphery (7). These requirements for maintenance
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and survival are paralleled when T cells are placed in an immunodeficient environment.
Specifically, naive CD8 T cells require host MHC class I and IL-7 expression to undergo
acute homeostatic proliferation in irradiated or RAG-deficient hosts (5, 8–11). IL-15 is not
required for initiating naive CD8 T cell acute homeostatic proliferation, but rather it helps to
sustain the process at later time points (12). In contrast, memory CD8 T cells proliferate in
the absence of MHC class I, but they require IL-7 and IL-15 for their maximum proliferation
in a lymphopenic setting (3, 5).
The identification of the mechanism of IL-15–mediated activity, namely transpresentation
(13, 14), led to the use of precomplexed IL-15 and soluble IL-15Rα as immunostimulants
(15–17). Thus, presentation of rIL-15 bound with high affinity to soluble rIL-15Rα drives
robust activation of cells expressing IL-2/15Rβ and the γC in vitro and in vivo. Memory
CD8 T cells and NK cells respond most vigorously, and IL-15/IL-15Rα (IL-15 complex)
treatment augments tumor clearance (16, 18, 19).
Surprisingly, naive CD8 T cells also respond to IL-15 complex, despite their low expression
level of IL-15Rβ (11, 16). Of note, the naive CD8 T cell response to IL-15 complex mimics
the response to cognate Ag in that the naive CD8 T cell population undergoes an expansion
phase and acquires an activated phenotype and effector functions, including the ability to
secrete IFN-γ and mediate Ag-specific cytolytic function. Importantly, no exogenous Ag
was required to initiate this response. Similarly, naive CD8 T cells undergoing acute
homeostatic proliferation in immunodeficient hosts acquire a memory phenotype with
increased expression of CD44, IL-2/IL-15Rβ and γC, Ly6C, and CD69 (10, 20, 21). Some
initial studies stated that naive CD8 T cells proliferating in a lymphopenic environment do
not acquire effector function after transfer (22), whereas others showed the acquisition of
potent effector responses (20, 21). However, this phenomenon requires multiple rounds of
division and develops relatively late posttransfer, which may explain the differences
between these studies. In addition, acute homeostatic proliferation results in the appearance
of long-term stable memory-phenotype CD8 T cells (23, 24). Thus, acute lymphopenic
proliferation and IL-15/IL-15Rα–induced proliferation of naive CD8 T cells result in the
acquisition of memory phenotypes, although IL-15 complex stimulation operates with more
rapid induction of proliferation (16).
Although acute slow homeostatic proliferation occurs without the addition of cognate Ag,
the process is dependent on the presence of MHC class I presenting self-peptide (8, 9, 25).
However, exogenous peptides derived from normal flora drive a subset of naive polyclonal
T cells to undergo rapid homeostatic proliferation (26). Furthermore, although some naive
TCR transgenic T cells, such as SIINFEKL-specific OT-I TCR transgenic CD8 T cells,
undergo massive proliferation when placed in a lymphopenic environment, this is not the
case with all naive CD8 T cells (9–11). This effect seems to be due, in part, to differences in
TCR triggering, whether due to TCR density, negative-regulator CD5 levels, TCR avidity,
or TCR promiscuity (8, 9, 27–29). These findings indicate that the strength of the TCR
stimulus is directly related to the extent of proliferation in response to lymphopenia (10).
Because naive CD8 T cells responding to IL-15 complex seem to undergo a similar
activation process as cells responding to lymphopenia (16, 21), we set out to compare the
requirements for induction of T cell activation by these conditions. The results indicated that
IL-15 complex-driven CD8 T cell activation operates through TCR signaling and not solely
through cytokine receptors. Understanding the mechanism through which IL-15 complex
modulates the immune system holds implications for the proper application of IL-15
immunotherapy.
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Materials and Methods
Mice
C57BL/6-CD45.2 mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and
the Charles River-National Cancer Institute. C57BL/6-CD45.1 mice were purchased from
Charles River-National Cancer Institute (Frederick, MD). B10.D2 mice (recipients of C4
transfers) were purchased from The Jackson Laboratory. The OT-I mouse line was
maintained as a C57BL/6-CD45.1 line on a Rag−/− background. FcRn−/− mice were a
generous gift from Dr. Lynn Puddington (University of Connecticut Health Center) (30).
β2m−/− mice and their respective C57BL/6-CD45.2 controls were purchased from Taconic
Farms (Germantown, NY). The F5 (31) and C4 (32) mice were generously provided by Dr.
Linda Cauley and Dr. Adam Adler, respectively (University of Connecticut Health Center).
All procedures were carried out under National Institutes of Health guidelines and were
approved by the University of Connecticut Health Center Animal Care Committee.
IL-15 treatment
Human IL-15 (hIL-15) was generously provided by Amgen (Thousand Oaks, CA). Mouse
rIL-15Rα–Fc chimeric molecule was purchased from R&D Systems (Minneapolis, MN).
hIL-15 and mouse rIL-15Rα–Fc, both suspended in PBS, were mixed and incubated for 30
min at 37°C. Each mouse, unless specifically noted, received 2.5 μg IL-15 alone or pre-
complexed with 15 μg mouse rIL-15Rα–Fc in 200 μl PBS i.p.
Purification and adoptive transfer of cells
Single-cell suspensions were created in HBSS by homogenizing spleens and lymph nodes
using frosted glass slides. RBCs were lysed using Tris-ammonium chloride buffer, and cells
were filtered through Nitex. CD44lo CD8 T cells (includes TCR transgenic T cells) were
enriched using a combination of anti–CD44-biotin and antibiotin microbeads (Miltenyi
Biotec, Auburn, CA), as previously described (33). In experiments comparing the
proliferation of CD44lo and CD44hi polyclonal CD8 T cells, both populations were purified
by flow cytometry using a FACSVantage SE (BD Biosciences, San Jose, CA). For CFSE
labeling, cells were incubated for 10 min at 37°C with CFSE (0.01 mM; Invitrogen,
Carlsbad, CA), the reaction was quenched with HBSS with 5% FCS (34), and the cells were
washed twice. CFSE-labeled cells were resuspended in PBS and injected i.v. into congenic
mice. Unless otherwise specified in the figure legends, the number of cells transferred was
between 1 × 105 and 3 × 105. For infections, 24 h post–OT-I transfer mice were infected i.v.
with 1 × 105 vesicular stomatitis virus expressing OVA (VSV-OVA).
Isolation of cells from tissues
Using frosted glass slides, spleen and lymph nodes were homogenized into single-cell
suspensions in HBSS/5% bovine serum. Lungs, liver, and brains were minced into small
pieces and incubated with collagenase buffer (RPMI 1640, 2% FCS, containing HEPES,
pen-strep, glutamine, gentamicin, CaCl2, MgCl2, and collagenase [100 U/ml; Invitrogen,
Carlsbad, CA]) for 1 h (lung and liver) or 30 min (brain) at 37°C under agitation. At the end
of incubation, remaining tissue pieces were crushed through 70-μm nylon mesh filter (BD
Biosciences). The resulting cells were pelleted and re-suspended in 44% Percoll buffer (GE
Life Sciences, Piscataway, NJ) and underlain with 67% Percoll buffer. Percoll gradients
were centrifuged at 1700 × g, and cells at the Percoll gradient interface were extracted,
washed, and resuspended in HBSS/5% bovine serum/HEPES, pen-strep, glutamine,
gentamicin.
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Flow-cytometric analysis
Cells were isolated at the indicated times and analyzed for the presence of donor cells using
CD45 or Thy1 allele status and their expression of surface markers and CFSE intensity. For
staining, lymphocytes were suspended in PBS/0.2% BSA/0.1% NaN3 (FACS buffer) at a
concentration of 5 × 106/100 μl and stained with indicated Abs at 4°C for 20 min, washed,
and fixed in PBS with 2% paraformaldehyde. Samples were acquired on a FACS-Calibur or
LSR II (BD Biosciences). Data were analyzed using FlowJo Software (Tree Star, Ashland,
OR).
Peptide activation and treatments
Congenic naive T cells were transferred into appropriate hosts (OT-I and F5 into B6 hosts)
that were subsequently treated as described in the figure legends. For peptide treatments,
mice received 100 μg of the respective peptide, unless stated otherwise. The peptide
sequences were as follows from N terminus to C terminus: SIINFEKL (OT-I–specific
epitope presented by H-2Kb) and ASNENMETM (F5-specific epitope from influenza virus
NP presented by H-2Db). For combination peptide and IL-15 complex treatment, peptides
were added to the mixture of IL-15 and IL-15Rα–Fc (as described above) prior to injection.
All treatments were given i.p.
Serial adoptive transfers and T cell-migration assay
We performed serial adoptive transfers to isolate OT-I T cells subjected to different
activating conditions and to test their migratory potential. Naive CD44lo CD45.1 OT-I cells
were transferred into naive CD45.2 B6 hosts; 1 d later, hosts were injected with IL-15
complex, a mixture of 100 μg SIINFEKL and IL-15 complex, or VSV-OVA. Four days
posttreatment, spleens were harvested and processed into single-cell suspensions.
Splenocytes were enriched for activated CD45.1 donor OT-I cells using MACS technology.
In short, single-cell suspensions were stained with CD45.1 biotin and enriched for CD45.1
OT-I using antibiotin microbeads and MACS LS separation columns, according to Miltenyi
Biotec protocols. Approximately 1 × 106 enriched activated CD45.1 OT-I cells, mixed with
CD45.2 naive B6 splenocytes to equalize the total number of cells transferred into each host,
were transferred into secondary CD45.2 B6 hosts. For the naive OT-I control, naive CD44lo
OT-I cells were isolated as described above, but hosts were left untreated. Two days
following secondary OT-I transfer, cells from spleen, peripheral lymph nodes (pLNs)
(inguinal, brachial, axillary, and cervical lymph nodes), lung, and liver were isolated and
processed as described above. Presence of CD45.1 donor OT-I cells was analyzed by flow
cytometry. The percentage of donor cells in each tissue was formulated as follows: the
number of CD45.1 donor OT-I cells in a particular tissue was divided by the total number of
CD45.1 donor OT-I cells in the spleen, pLNs, liver, and lung and then multiplied by 100.
Results
Naive CD8 T cell response to IL-15 complex is MHC class I dependent
As we previously illustrated, naive CD8 T cells acquire an activated phenotype and effector
function in response to IL-15 complex (16). Although cognate Ag is not required for these
effects, it is not known whether the response is MHC class I dependent. To test this
possibility, we transferred CFSE-labeled CD44lo CD45.1 naive OT-I TCR transgenic CD8 T
cells (Fig. 1A) into sublethally irradiated (500 rad) CD45.2 B6 and MHC class I-deficient
(β2m−/−) mice on day −1. Hosts were irradiated to prevent rejection of donor cells in
β2m−/− mice. On day 0, B6 and β2m−/− mice were treated with PBS or IL-15 complex (2.5
μg IL-15 and 15 μg sIL-15Rα–Fc; doses used for all experiments), and splenocytes were
analyzed on day 4 posttreatment for OT-I proliferation. As expected, the naive CD44lo OT-I
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cells underwent homeostatic proliferation in irradiated B6 hosts, and this proliferation was
substantially augmented with IL-15 complex treatment (Fig. 1A). In contrast, in untreated
irradiated β2m−/− hosts, naive OT-I CD8 T cells did not proliferate. With IL-15 complex
treatment, only a low level of proliferation was induced in β2m−/− mice, as evidenced by
blunted CFSE dilution and reduced cell numbers (Fig. 1A). The minor response detected in
β2m−/− hosts may be due to the interaction of OT-I cells with other MHC class I+ donor
cells or with MHC class II present in the host (29, 35). Thus, the naive CD8 T cell response
to IL-15 complex was largely dependent on the presence of MHC I.
Contrary to naive CD8 T cells, the proliferation of CD44hi CD8 T cells in a lymphopenic
environment is not MHC class I dependent (2, 3). To test whether this was also the case with
IL-15 complex, sorted CFSE-labeled CD44hi Thy1.1 and CD44lo CD45.1 polyclonal CD8 T
cells were transferred together into sublethally irradiated (550 rad) CD45.2/Thy1.2 B6 and
β2m−/− hosts on day −1. On day 0, B6 and β2m−/− mice were treated with PBS or IL-15
complex, and splenocytes were analyzed for the proliferation of donor cells on day 4.
Consistent with the OT-I data, the proliferation of CD44lo polyclonal CD8 T cells was
greatly reduced in β2m−/− hosts compared with B6 hosts (Fig. 1B). In contrast, treatment
with IL-15 complex substantially enhanced proliferation of memory-phenotype cells in B6
hosts and, to a lesser extent, in β2m−/− hosts (Fig. 1C). The results indicated that the
response of naive CD8 T cells to IL-15 complex had a greater dependence on MHC class I
than did memory-phenotype cells, suggesting that complex treatment mimicked events seen
in a lymphopenic situation (3, 8, 10).
FcRn partially regulates IL-15/IL-15Rα complex pharmacology
Although β2m−/− mice lack MHC class I expression, β2m is also required for expression of
the neonatal Fc receptor FcRn (36). FcRn plays an important role in IgG catabolism through
IgG uptake and recycling, such that FcRn deficiency results in reduced IgG half-life.
Because the IL-15Rα component of IL-15 complex contains an IgG Fc region, we
investigated whether β2m expression affected complex half-life. To this end, B6 and β2m−/−
hosts were administered equal amounts of IL-15 complex, and serum IL-15 levels were
measured at various times after treatment by ELISA (16). At early time points, more IL-15
was detected in the serum of β2m−/− mice compared with control mice (Fig. 2A). However,
IL-15 decayed more rapidly in β2m−/− mice, and the total amount of available IL-15 was
~60% of that in B6 mice, as measured by calculating the area under each curve. The role of
FcRn in this phenomenon was directly assessed using FcRn−/− hosts. IL-15 serum half-life
exhibited similar kinetics in FcRn−/− hosts as in β2m−/− hosts, although no early spike in
IL-15 levels was noted as in β2m−/− mice (Fig. 2B). As seen in β2m−/− mice, we noted that
the total amount of available IL-15 in FcRn−/− mice was ~60% of that in B6 mice. We also
measured the proliferation of naive OT-I cells in sublethally irradiated B6 and FcRn−/−
hosts. Without complex treatment, OT-I cells divided equally well in sublethally irradiated
FcRn−/− and B6 hosts (Fig. 2C). However, OT-I cell proliferation was partially reduced in
IL-15 complex-treated FcRn−/− mice compared with B6 hosts, which may be explained by
the reduction in IL-15 half-life and total availability (Fig. 2B). Nonetheless, proliferation of
naive OT-I cells in FcRn−/− mice was substantially greater than that obtained in β2m−/−
mice (Fig. 1A). Thus, although the lack of FcRn influenced the naive CD8 T cell response in
β2m−/− mice, the majority of IL-15 complex-driven proliferation was mediated via MHC
class I recognition. Furthermore, the reduced in vivo half-life of IL-15 complex in β2m−/−
mice may explain the decreased response of CD44hi polyclonal CD8 T cells to IL-15
complex in these mice.
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TCR avidity for self-MHC controls responsiveness to IL-15 complex
Not all naive CD8 T cells respond equally well to a lymphopenic environment (4), and this
finding has been linked to TCR avidity (28). Because the CD8 T cell response to IL-15
complex was also MHC class I dependent, it was of interest to test whether relative TCR
avidities affected the response. We first examined whether the response of naive CD8 T
cells to IL-15/IL-15Rα complex treatment exhibited heterogeneity. CFSE-labeled CD45.1
CD44lo naive polyclonal B6 CD8 T cells were transferred into normal CD45.2 B6 hosts on
day −1 that were then treated with PBS or IL-15 complex on day 0. Concurrently, CFSE-
labeled CD45.1 CD44lo naive polyclonal CD8 T cells were also transferred into CD45.2 B6
hosts sublethally irradiated (550 rad) 1 d earlier. At 4–5 d posttreatment, splenocytes were
examined for CFSE dilution. A robust proliferative response was seen only when the mice
were exposed to IL-15 complex (Fig. 3A). Interestingly, the polyclonal CD8 T cell
population divided in an asynchronous fashion, in contrast to OT-I cells (Fig. 1), with some
cells undergoing extensive division and others barely dividing. Thus, not all naive
endogenous CD8 T cells responded to IL-15 complex to the same extent. Similarly, although
the proliferative response was not as robust as in IL-15 complex-treated hosts, polyclonal
CD8 T cells also exhibited an asynchronous division in sublethally irradiated hosts (Fig.
3A).
To more closely examine how TCR avidity may influence the response to IL-15 complex,
we compared the response of naive TCR transgenic CD8 T cells of different specificities
and distinct TCR avidities (28). To this end, naive CFSE-labeled CD44lo CD45.1 OT-I
(specific for SIINFEKL peptide presented by H-2Kb), F5 (specific for influenza virus NP
peptide presented by H-2Db), and C4 (specific for influenza virus HA peptide presented by
H-2Kb) TCR transgenic CD8 T cells were transferred into CD45.2 B6 or B10.D2 (for C4)
mice on day −1. On day 0, B6 hosts were treated with PBS or IL-15 complex. TCR
transgenic T cells were also transferred into CD45.2 B6 mice sublethally irradiated (550 rad)
1 d in advance. On day 5 posttreatment, donor cells were analyzed for CFSE dilution. In an
immunodeficient environment (sublethally irradiated hosts), OT-I and C4 cells divided
extensively, whereas F5 cells did not divide (Fig. 3B). Thus, the TCR avidity of F5 CD8 T
cells is insufficient to drive homeostatic proliferation. Interestingly, the response of OT-I,
F5, and C4 TCR transgenic CD8 T cells to IL-15 complex paralleled the response to
lymphopenia. This was not due to differences in CD122 or CD132 expression levels
between the TCR transgenic T cells (data not shown). Compared with lymphopenia-driven
expansion, proliferation was better with IL-15 complex treatment in all cases, with some
limited proliferation observed with F5 T cells (Fig. 3B).
IL-15 complex enhances the naive CD8 T cell response to cognate peptide
Providing naive CD8 T cells their cognate peptide during acute homeostatic proliferation
enhances their proliferative response (8, 10). Therefore, we examined whether IL-15
complex treatment, along with cognate peptide, would further enhance the naive CD8 T cell
response to IL-15 complex. CFSE-labeled CD45.1 CD44lo OT-I and F5 cells were
transferred into separate CD45.2 B6 hosts on day −1. On day 0, hosts were treated with
PBS, cognate peptide, IL-15/IL-15Rα, or cognate peptide and IL-15/IL-15Rα. On day 5,
donor cell division was measured by flow cytometry. Peptide alone induced significant
proliferation in F5 cells, whereas IL-15 complex was a poor inducer of cell division.
However, the F5 cell response was greatly enhanced when IL-15 complex and cognate
peptide were administered (Fig. 4A). Similar results were obtained with OT-I cells, although
their response to IL-15 complex alone was much greater than that of F5 cells (Fig. 4B). We
also examined the accumulation of the different cell populations in each case. Peptide
treatment alone, although inducing cell division, did not result in significant accumulation of
responding cells, likely due to deletion (Fig. 4). Treatment with the combination of cognate
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peptide and IL-15 complex seemed to be synergistic, resulting in substantial accumulation of
cells. In additional studies in which OT-I cells and F5 cells were cotransferred, OT-I cells
outcompeted F5 in each of the responses (Supplemental Fig. 1). This finding further
supported the concept that TCR avidity was controlling the response to IL-15/IL-15Rα
complex. Nevertheless, these results suggested that IL-15 complex acts selectively on Ag-
activated CD8 T cells and could serve as an adjuvant for Ag-specific responses.
Furthermore, the cell-accumulation data illustrated that naive CD8 T cells normally
unresponsive to IL-15 complex were more responsive when TCR was engaged.
We also examined the effect of peptide and IL-15 complex treatment on T cell migration to
nonlymphoid tissues. CD45.1 CD44lo naive OT-I cells were transferred into CD45.2 B6
hosts on day −1, and on day 0 these mice were treated with PBS, SIIN-FEKL peptide, IL-15
complex, or SIINFEKL peptide and IL-15 complex (peptide/IL-15 complex). Five days
posttreatment, mice were sacrificed, and various tissues were examined for the presence of
the OT-I donor population. IL-15 complex treatment increased OT-I cell numbers in the
lung, as well as in the spleen. An even larger OT-I donor population was present in both
tissues of mice treated with peptide/IL-15 complex compared with IL-15 complex treatment
alone (Fig. 5). A similar pattern was seen in the liver (data not shown). Comparable results
were obtained when F5 cells were transferred and the treatments administered, although, as
expected, fewer total F5 cells compared with OT-I cells, were recovered from the organs
(Supplemental Fig. 2). When the brain, a more immunoprivileged tissue (37, 38), was
examined, very few OT-I CD8 T cells were present in control, peptide- or IL-15 complex-
treated mice. In contrast, a sizable population of CD8 T cells was present in the brains of
peptide/IL-15 complex-treated mice (Fig. 5).
The previous data suggested that IL-15 complex treatment, along with peptide
immunization, enhanced lymphocyte migration. Therefore, we examined the expression of
various adhesion molecules after treatment. All treatments uniformly upregulated CD11a
(Fig. 5B). Treatment with IL-15 complex alone weakly upregulated CD43 and did not
induce CD62L downregulation, but it modestly enhanced CD44 expression. Peptide
treatment alone strongly induced CD43 expression, modestly downregulated CD62L
expression, and greatly upregulated CD44 levels. Peptide/IL-15 complex was the most
effective at CD43 induction and CD62L downregulation, and it strongly induced CD44
expression. Thus, IL-15 complex enhanced the proliferative response to cognate Ag, and the
combination of IL-15 complex and Ag also resulted in the modulation of adhesion receptors
involved in migration and enhanced function.
We performed serial adoptive transfers to formally test whether IL-15 complex altered the
migration potential of the responding CD8 T cells. CD45.1-naive CD44lo OT-I cells were
transferred into CD45.2 B6 hosts on day −1 and then treated with IL-15 complex, peptide/
IL-15 complex, or VSV-OVA on day 0. VSV-OVA infection causes similar changes in cell-
surface phenotype as does peptide/IL-15 complex (data not shown) and was used as a
positive control for migration potential to tertiary sites. On day 4 posttreatment, splenocytes
were harvested and enriched for donor OT-I cells. A total of 1 × 106 CD45.1 OT-I cells
from each group, including naive CD44lo OT-I cells as a control, were transferred into
secondary CD45.2 B6 hosts. Two days after secondary transfer, hosts were sacrificed, and
the presence of donor OT-I cells was determined in several tissues (Fig. 6). Naive OT-I cells
were mainly found in the spleen and pLNs. In contrast, VSV-OVA–experienced OT-I cells
were found in the spleen, as well as in the lungs and liver, with few present in the pLNs.
Cells from IL-15 complex-treated mice behaved similarly to naive CD8 T cells, whereas the
migration pattern of peptide/IL-15 complex-treated cells resembled that of virus-activated
OT-I cells. Overall, the data support the notion that IL-15 complex treatment can augment
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CD8 T cell activation and enhance migratory capabilities, both of which are necessary
outcomes of effective immunotherapy.
Discussion
Our previous work highlighted the intriguing ability of IL-15Rα-complexed IL-15, but not
IL-15 alone, to activate naive CD8 T cells (16). This response was Ag independent, but we
now show that the process required expression of MHC class I. Furthermore, the ability of a
naive CD8 T cell to respond to IL-15 complex correlated with TCR avidity for self-
peptide:MHC class I. Intriguingly, the response was augmented, as well as altered, by
providing a stronger TCR stimulus. In particular, IL-15 complex induced a lymphoid-
migration profile, whereas agonist peptide/IL-15 complex induced a nonlymphoid-migration
profile. These latter results point out some important considerations for the use of IL-15
complex as a therapeutic and may help to explain some recent findings.
Recent work revealed similarities in the naive CD8 T cell response to IL-15 complex and
IL-2α/IL-2 complex (IL-2 complex). Similar to the effects of IL-15 complex treatment (16),
naive CD8 T cells treated with IL-2 complex in vivo proliferate, acquire an activated/
memory phenotype, produce effector cytokines, and kill in an Ag-specific manner (39). In
apparent contrast to our findings, IL-2 complex-driven naive CD8 T cell activation is
classical MHC class I independent (39). However, this study used H-2Kb and H-2Db
double-deficient mice, which still express other MHC class I molecules. Indeed, another
report found that the CD8 T cell response to IL-2 complex is MHC class I dependent when
using Kb−/− Db−/− β2m−/− triple-knockout mice (35), ensuring that classical and
nonclassical MHC class I molecules are absent. An additional study found that in CD132−/−
(γC−/−) mice, in which IL-2 and IL-15 levels are abnormally high, naive CD8 T cell
proliferation is only modestly affected by the absence of MHC class I (40), perhaps as a
result of the combined effects of both cytokines. Overall, these findings further illustrate the
close relationship between factors controlling lymphopenia-driven and cytokine complex-
driven naive CD8 T cell activation.
One caveat with the use of β2m−/− mice to study the response to an IgG-Fc region-
containing molecule is the potential role of FcRn in IgG catabolism (36). This issue could be
a confounding factor in our studies and that of Cho et al. (35). In fact, we found that the in
vivo half-life of IL-15 was modestly and similarly reduced in β2m−/− and FcRn−/− mice.
However, IL-15 complex-driven naive CD8 T cell proliferation remained robust in FcRn−/−
mice, whereas it was substantially diminished in β2m−/− mice. Thus, the absence of FcRn
cannot account for the lack of proliferation seen in β2m−/− mice. Not surprisingly, the
activity of IL-2/α–IL-2 was also recently shown to be dependent, in part, on FcRn (41).
Our data indicated that not all naive CD8 T cells responded with the same intensity to IL-15
complex. A similar spectrum of proliferation is seen when naive CD8 T cells are placed in a
lymphopenic environment (9). Recent work noted that TCR avidity for self-peptide:MHC
class I regulates the CD8 T cell response to lymphopenia. Thus, in a lymphopenic
environment, T cells with high-avidity TCRs proliferate more vigorously than do T cells
with lower-affinity TCRs (28). Our results demonstrated a direct correlation between the
relative ability of a naive CD8 T cell to respond to IL-15 complex or to lymphopenia.
Furthermore, the response to IL-15 complex positively correlated with TCR avidity, as
measured by acute homeostatic proliferation. Greater TCR signaling may confer heightened
responsiveness to homeostatic cytokines, such as IL-7, especially in more competitive
situations (28, 42). Thus, the cytokine-driven response to lymphopenia also requires a level
of tonic TCR signaling, although there is some evidence of TCR-independent cytokine-
mediated proliferation in lymphopenic settings (29). There is also a link between IL-15
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adjuvanticity and TCR avidity, because IL-15 administration causes the outgrowth of
higher-avidity CTLs in response to infection (43). Our cotransfer studies reiterated the
concept that high-avidity clones may outpace low-avidity clones in response to IL-15
complex in the presence or absence of Ag. Given these findings, IL-15 complex may operate
as an effective immunotherapy by preferentially stimulating the expansion of high-avidity
naive or effector CD8 T cells, in part through TCR- and MHC-mediated signals.
Of particular interest was our finding that IL-15 complex and peptide/IL-15 complex
treatments caused distinct changes in the expression of surface markers associated with
migration. Although complex and peptide/IL-15 complex caused upregulation of CD11a and
CD44, only peptide/IL-15 complex caused significant down-regulation of CD62L and
upregulation of CD43. CD43 plays a role in the migration of effector cells from secondary
lymphoid tissues to tertiary sites of inflammation, in particular the brain (44, 45).
Furthermore, the concomitant downregulation of CD62L and up-regulation of CD44 also
promote migration to tertiary sites (46–48). Overall, the changes in surface expression of the
receptors correlated with the migratory behavior of the cells. CD8 T cells activated by
peptide/IL-15 complex treatment migrated more readily to nonlymphoid tissues compared
with cells activated with IL-15 complex alone. The efficacy of IL-15 complex in tumor
immunotherapy may hinge, in some cases, on the ability of IL-15 complex to alter effector
cell migration. For example, partial regression of solid tumors is induced by IL-15 complex
by activation of intratumor tumor-specific CD8 T cells (19). The investigators noted that
IL-15 complex treatment more effectively stimulated intratumor CD8 T cells than peripheral
CD8 T cells, and IL-15 complex treatment did not enhance CD8 T cell migration into
tumors. Given our current results, the robust response of intratumor CD8 T cells may be
explained by access and interaction of intratumor, but not peripheral, CD8 T cells with
cognate Ag. Without access to tumor Ag, IL-15 complex-activated tumor-specific CD8 T
cells may not efficiently enter pre-existing tumors because of the lack of effective
modulation of homing receptors that promote extralymphoid migration. Thus, stronger TCR
stimulation, in conjunction with IL-15R signaling, may help to spur migration of CTLs into
tertiary tissues and, possibly, tumors.
Overall, our findings highlight the ability of IL-15 complex to specifically induce activation
and proliferation of naive CD8 T cells expressing high-avidity TCRs. This process is
dependent on the expression of self-peptide:MHC class I. This feature of the IL-15 complex
response may mimic the action of IL-15 during immune responses, in which higher-avidity
T cells may compete more effectively for homeostatic cytokines. IL-15 complex holds
promise as an immunotherapy, but further study of the synergy between TCR and IL-15R
signaling is required to aid in the design of therapeutic protocols.
Abbreviations used in this paper
hIL-15 human IL-15
IL-2 complex IL-2α/IL-2
peptide/IL-15 complex SIINFEKL peptide and IL-15 complex
pLN peripheral lymph node
VSV-OVA vesicular stomatitis virus expressing OVA
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FIGURE 1.
Naive CD8 T cell response to IL-15 complex requires MHC class I. A, A total of 5 × 105
CFSE-labeled naive CD45.1 CD44lo OT-I TCR transgenic CD8 T cells was injected i.v. into
CD45.2 B6 or β2m−/− hosts that were sublethally irradiated (500 rad) 12 h earlier. One day
later, mice were injected i.p. with PBS or 2.5 μg hIL-15 + 15 μg mIL-15Rα–Fc. Four days
after treatment, donor cell proliferation and accumulation were examined in the spleen. A
total of 5 × 105 CFSE-labeled CD45.1 CD44lo polyclonal CD8 T cells (B) and 3 × 105
CFSE-labeled Thy1.1 CD44hi polyclonal CD8 T cells (C) were coinjected i.v. into CD45.2
Thy1.2 B6 and β2m−/− mice that were sublethally irradiated (500 rad) 12 h earlier. One day
later, mice were injected i.p. with PBS or 2.5 μg hIL-15 + 15 μg mouse IL-15Rα–Fc. Four
days later, donor cell proliferation and accumulation were examined in the spleen. Data are
representative of at least two experiments (n = 3).
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FIGURE 2.
Naive CD8 T cell response to IL-15 complex is partially dependent on FcRn. A, B6 and
β2M−/− mice were injected i.p. with 2.5 μg hIL-15 + 15 μg mouse IL-15Rα–Fc, and hIL-15
was measured in the blood at various time points after injection (0, 0.5, 1, 2, 4, 8, 24, 48, 72,
and 96 h) by ELISA. B, As in A, but using B6 and FcRn−/− mice and evaluating at ~0.25,
0.5, 1, 2, 4, 8, 24, 48, 72, and 96 h. C, A total of 4.0 × 105 CFSE-labeled CD45.1 CD44lo
OT-I CD8 T cells were injected i.v. into CD45.2 B6 or FcRn−/− mice sublethally irradiated
(500 rad) 12 h earlier. One day later, mice were treated with PBS or 2.5 μg hIL-15 + 15 μg
mouse IL-15Rα–Fc. Four days later, donor cell proliferation and accumulation were
examined in the spleen. Data are representative of at least two experiments (n = 2–4).
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FIGURE 3.
Naive CD8 T cell response to IL-15 complex is heterogeneous. CD44lo polyclonal CD8 T
cells (A) or OT-I, F5, or C4 CFSE-labeled CD45.1 CD44lo CD8 T cells (B) were injected
i.v. into irradiated (500 rad) or normal CD45.2 B6 or B10.d2 (for C4) mice. One day later,
the normal B6 mice received PBS or 2.5 μg hIL-15 + 15 μg mouse IL-15Rα–Fc i.p. Five
days after treatment, donor cell proliferation was examined in the spleen.
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FIGURE 4.
TCR avidity controls the CD8 T cell response to IL-15 complex. F5 (A) or OT-I CFSE-
labeled CD45.1 CD44lo (B) CD8 T cells were injected i.v. into B6 mice. One day later, mice
were treated i.p. with PBS, IL-15 complex, or with F5-NP peptide (100 μg) or SIINFEKL
(6.25 μg), or with peptide plus IL-15 complex. Five days after treatment, donor cells were
examined for proliferation and total cell numbers in the spleen. Data are representative of
two similar experiments (n = 3).
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FIGURE 5.
Cognate peptide increases and alters the naive CD8 T cell response to IL-15 complex. A,
CD45.1 CD44lo OT-I CD8 T cells were i.v. transferred into CD45.2 B6 mice. One day later,
mice were treated i.p. with PBS, 100 μg SIINFEKL peptide,2.5 μg hIL-15 + 15 μg
IL-15Rα–Fc, or 100 μg SIINFEKL and 2.5 μg IL-15 + 15 μg IL-15Rα–Fc. Donor cell
accumulation was examined in the spleen, lungs, and brain. B, Donor cells from the spleen
were analyzed for expression of the indicated proteins by flow cytometry. Shaded graph =
PBS, thin line = IL-15 + IL-15Rα–Fc, thick line = peptide, dashed line = peptide + IL-15 +
IL-15Rα–Fc. Data are representative of at least two experiments (n = 3–4).
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FIGURE 6.
Activation with cognate peptide and IL-15 complex alters the migratory ability of CD8 T
cells. A total of 6 × 106 congenic naive OT-I cells were transferred into B6 hosts on day −1
and then were treated i.p. with 2.5 μg IL-15 + 15 μg IL-15Rα–Fc, 100 μg SIINFEKL and 2.5
μg IL-15 + 15 μg IL-15Rα–Fc, or 1 × 105 PFU VSV-OVA on day 0. Four days
posttreatment, splenocytes were harvested and enriched for donor OT-I cells. OT-I cells (1 ×
106) from each group, including fresh CD44lo naive OT-I cells, were transferred i.v. into
secondary untreated B6 hosts. Two days after secondary transfer, mice were sacrificed, and
the presence of donor OT-I cells was determined in spleen, pLNs, liver, and lung. Data are
depicted as the percentage of cells in a tissue out of four tissues tested and are representative
of two experiments (n = 3).
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